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This work describes the development and validation of a microbiological method using the cylinder-plate assay for quantitative
determination of imipenem in powder for injection. The aim was to obtain a low-cost  and suitable methodology that  can be
alternative to physicochemical  techniques already described, contributing for the quality control of this antibiotic. Firstly, the
analytical conditions were optimized, testing the microorganism, inoculum concentration and best range of sample and standard
concentrations, in a way that provides the adequate measurement of the inhibition halos. Staphylococcus epidermidis ATCC 12228
was selected as test microorganism, as well as 2.0 % of inoculum concentration. The validation protocol followed the official
guidelines,  and the parameters  evaluated were linearity,  precision (intermediate precision and repeatability) and accuracy.  All
standard curves ranging 0.5-2.0 µg/mL showed r values higher than 0.999, and ANOVA confirmed that were no deviation from
linearity (p-value > 0.05). The method also proved to be precise with RSD (relative  standard deviation) values ranging 0.28-0.64
for repeatability and 2.49 for intermediate precision. It was performed three days of experiments, being three assays of eight plates
a day.  The drug mean content was 101.05%. Accuracy  was assessed by recovery test,  with standard recovery percentage  of
101.70-107.90% (mean recovery = 104.86%), which was considered satisfactory. Therefore, the proposed microbiological method
was considered validated and suitable for application in quantitative determination of this drug, being useful for quality control
routine.
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Introduction 
Imipenem  (Figure  1),  or  chemically  (5R,6S)-3-[2-
(aminomethylideneamino)  ethylsulfanyl]-6-[(1R)-1-
hydroxyethyl]-7-oxo-1-azabicyclo  [3.2.0]  hept-2-ene-2-
carboxylic acid, is a broad spectrum beta-lactam antibiotic
belonging to the subgroup of carbapenems, which are drugs
structurally  composed  of  a  pentacyclic  thiazolidinic  ring
attached  to  the  nitrogen  of  the  beta-lactam  ring  by  a
tetrahedral  carbon  atom  (1).  Derived  from  thienamycin,
imipenem is  the  oldest  carbapenems  available  for  clinical
use, approved in 1986 in the USA (2). It has activity against
most of the Gram-positive and Gram-negative, aerobic and
anaerobic  bacteria  (1),  including  those  beta-lactamase-
producing bacterial  pathogens. This occurs due the greater
stability of pentacyclic  ring that  is attached to beta-lactam
ring against the action of these enzymes (3). However, drug-
resistance has been reported in Gram-negative bacteria, for
example in some strains of Pseudomonas aeruginosa (4).
Clinically, imipenem is used to treat several  polymicrobial
infections,  such  as  pneumonia  and  complicated
gastrointestinal tract infections. The recommended dose is 2
g/day in adults with normal renal  functions (4).  However,
imipenem  is  hydrolyzed  by  a  renal  dehydropeptidase
(dehydropeptidase  I)  (3),  being  inactivated,  requiring  co-
administration of cilastatin, an inhibitor of this enzyme in
clinical use. Imipenem and cilastatin are marketed as powder
for injection (1:1, w/w) in doses of 250 and 500 mg, since
they  are  not  absorbed  orally.  Most  often  they  are  given
intravenously by infusion, but in case of treatment of less
severe infections, they can be given intramuscularly (in dose
of 750 mg) (5). 
Figure 1. Chemical structure of imipenem.
A review of literature shows many analytical studies applied
to imipenem in biological fluids, involving HPLC-DAD (6-
8),  and spectrophotometric/chemometric  technique (9).  On
the  other  hand,  for  pharmaceutical  dosage  forms,  the
literature  reports  derivate  spectrophotometric  (10,11),  and
RP-UPLC  method  for  quantitation  of  imipenem  related
impurities  (12).  In  fact,  antibiotics  play  an  increasingly
important role in pharmacotherapy because of their wide use
in  the  clinical  practice,  so  it  is  extremely  important  to
develop  alternative  methods  that  allow  their  analytical
determination in existing pharmaceutical forms (13).
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Microbiological  assays  have  been  widely  used  to
determinate antibiotic drugs along the years (13-15). These
methods are recommended by several pharmacopoeias, like
the USP and European  Pharmacopoeias  (16-18).  Different
techniques are described in microbiological assays that are
used for antibiotic drugs to determine antibacterial activity,
like  paper  disk  procedures,  standard  broth  microdilution
assay,  and  cylinder-plate  assay.  The  evaluation  of  the
inhibitory effect of the antibiotic on the growth of the test
microorganisms  makes  possible  its  quantitative
determination by means of logarithmic relation between the
drug concentration and antimicrobial potency (13).
Therefore,  microbiological  assays can be an alternative  to
the  physicochemical  methods  like  HPLC,  not  requiring
sophisticated equipment or toxic solvents, and being viable
to  use  even  in  small  laboratories.  For  carbapenems,  two
microbiological  cylinder-plate  assays  are  described  for
meropenem and doripenem, both developed to determine the
drugs in powder for injections (13,19). For imipenem, this
methodology is absent. Thus, the present manuscript reports
the development and validation of microbiological assay for




Imipenem  reference  standard  (85.5%)  was  obtained  from
Sigma-Aldrich  (St.  Louis,  Missouri,  EUA).  Powder  for
injection containing 500 mg of imipenem monohydrate and
500  mg  of  Cilastatin  sodium  was  purchased  from  ABL
Antibiotics  (Cosmópolis,  SP,  Brazil).  For  microbiological
assay, DifcoTm Antibiotic Media number 11 obtained from
Interlab®  (São  Paulo,  SP,  Brazil),  and  Grove  Randall
number  1  agar  from  Merck  (Darmstadt,  Germany)  were
used.  All  solutions  were  prepared  in  distilled  water  and
sterilized before each experiment. Analytical grade sodium
chloride of  the Synth LTDA (São Paulo,  SP,  Brazil)  was
used for preparation of inoculum suspension.
Microbiological assay
Microorganism and inoculum
Staphylococcus  epidermidis ATCC  12228  was  chosen  as
microorganism test. The strains were cultivated with number
1 agar  and kept  in freezer.  One day before  the assay, the
microorganism was inoculated with the same agar that was
kept  at  35°  C  for  24  hrs.  The  inoculum suspension  was
prepared  using  NaCl  0.9%  sterile  solution,  which  was
standardized with 25 ± 2% of transmittance at 580 nm, using
a spectrophotometer Analyser® Model 800 (São Paulo, SP,
Brazil). NaCl 0.9% solution was used as blank of absorption.
Portions of this inoculum suspension were  inoculated into
erlenmeyer  flasks  containing  number  11  agar  in  order  to
obtain a concentration of 2% inoculum, being kept at 47 ± 2°
C. Then, 6 mL of this inoculum (2%) were applied over the
base layer (composed by 20 mL of number 11 agar) in the
plates.
Standard and sample solutions
Imipenem  standard  solution  was  prepared  for  each
experiment.  Sterile distilled water was used as solvent for
drug  solubilization  and  subsequent  dilutions.  An  amount
equivalent to 10 mg of imipenem standard was accurately
weighed  and  transferred  to  100  mL  volumetric  flask.
Distilled water was added to make up to volume and give
the  final  concentration  of  the  stock  solution.  This  stock
solution  (imipenem  100  µg/mL)  was  used  during  the
experiment.  For  sample  solution,  the  same  protocol  was
applied  starting  from  an  amount  equivalent  to  10  mg  of
imipenem powder for injection. Both stock solutions (100
µg/mL) were used in the subsequent dilutions.
Cylinder-plate assay
The 3 x 3 design was performed with 8 plates  for  assay,
following the procedure recommended by official reference
(17). The 100 x 20 mm petri dishes were filled with number
11 agar in two separate layers: the base layer and the surface
layer. The base layer was composed by 20 mL of number 11
agar  and  the  surface  layer  was  composed  by  6  mL  of
inoculum (2%).  Six 8 mm cylinders were distributed over
the surface layer in each plate, for subsequent application of
the drug solutions.
These cylinders were filled with 200 µL of standard solution
or sample solution in three different concentrations of each,
and then, the plates were incubated in dry air oven at 37 °C
for 18 hours. Inhibition halos were measured using a digital
caliper  Starret®  and the  data  collected  were  analyzed  for
antimicrobial  potency calculations,  by correlating diameter
of inhibition halos and log of drug concentration.
Preliminary assays
Two  concentrations  were  tested  for  inoculum  suspension
(1% and 2%) in a preliminary assay with 20 plates, being 10
plates  with  each  concentration  of  inoculum.  At  the  same
preliminary  experiment,  two  ranges  of  concentrations  for
standard and sample solutions were tested: 1.0; 2.0 and 4.0
µg/mL and  2.0;  4.0  and  8.0  µg/mL,  which  was  prepared
from the stock solutions. In the plates with 1% of inoculum
concentration, the two ranges of dilutions for standard and
sample solutions were tested (5 plates for each group). The
same procedure was done for the plates with 2% inoculum
concentration.  The  results  were  compared  to  evaluate  the
microorganism growth and inhibition halo measurements.
Another  preliminary  experiment  was  performed  from
observation  of  previous  results,  using  2%  of  inoculum
concentration  and  testing  three  new  concentrations  for
standard  and  sample  solutions:  0.5;  1.0  and  2.0  µg/mL.
Here, the focus was the inhibition halo sizes, which must to
be adequate for practical measurement and to avoid possible
interferences.
Method validation
Linearity  and  Precision  (repeatability  and  intermediate
precision)
To  evaluate  linearity,  three  concentrations  were  prepared
from the stock solutions of imipenem standard.  The stock
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solution  was  diluted  in  volumetric  flasks  (10  mL)  with
sterile distilled water and the final concentrations obtained
was  0.5;  1  and  2  µg/mL.  Linearity  was  assessed  by
constructing  nine  standard  curves  in  three  days  of  assay,
being  three  curves  a  day,  and  each  curve  considered  the
results from eight plates.  The analysis of linear  regression
was performing using least squares regression method, and
statistical  analyses  to  validate  the  results  were  performed
using ANOVA. The repeatability (intra-day) was evaluated
comparing results of three eight-plate assays, performed in
the same day at the same conditions, and the intermediate
precision was evaluated comparing results of three different
days of experiment, being three assays of eight plates a day.
Relative standard deviation (RSD) was calculated.
Accuracy
The  accuracy  was  assayed  by  recovery  method.  Known
quantities  of  standard  solutions  were  added  to  sample
solutions with nominal concentrations of 0.5; 1 e 2 µg/mL.
The amount of standard added corresponds to 10% of these
solutions concentrations. Then, the recovery percentages of
the standard added were calculated. The results from three
eight-plate assays performed in the same day were used in
the calculations. Relative standard deviation (RSD) from the
analyses was also calculated.
Results and discussion
Methodology optimization 
The success in a method validation is widely dependent of
well-established  analytical  conditions.  In  special  case  of
microbiological methodologies, where there is a great source
of variations that may interfere on analysis, is important the
optimization of the conditions in order to obtain a reliable
and reproductive method. The microbiological assay using
the cylinder-plate assay and 3x3 design (three concentrations
of  standard  and  sample  in  the  same  plate)  has  been
recommended  by  official  references  (16),  being  used  for
many antibiotics. The principle of this method is the drug
diffusion  on  an  agar  surface  inoculated  with  a
microorganism, producing a inhibition zone of growth that is
measured (20-22) and allows to determine the drug potency
and  to  detect  small  variances  in  biological  activity.  Agar
diffusion methods have  been  the  methodology chosen  for
water-soluble antibiotics (23). 
For  the  present  study,  the  culture  medium  was  selected
based on similar methodologies described for others similar
carbapenems:  meropenem and doripenem (13,18).  As  test
microorganism,  Staphylococcus  epidermidis was  selected
due availability as well as its adequate growth in the culture
media selected and reproducibility on measurement of halos.
Testing  inoculum  concentration,  the  better  response  was
observed  by  using  the  higher  concentration  (2%),  whose
growth was better in terms of intensity and uniformity. 
From  this  result,  another  preliminary  experiment  tested
different dilutions for standard and sample using plates with
2%  of  inoculum  concentration.  The  drug  concentrations
tested were 1.0; 2.0; 4.0 µg/mL and 2.0; 4.0; 8.0 µg/mL. It is
very  important  for  a  better  and  more  reliable  measure  of
inhibition halos to have adequate separation between them in
the surface layer. For it, it is important to find a range with a
good  response  from  geometric  progression  used  in  the
calculations.  The  two  concentration  ranges  tested  did  not
provide  a  good  response  in  terms  of  reproducibility  and
inhibition  halo  sizes,  as  expected.  In  this  case,  it  was
observed  a  very  large  halo  size.  Based  on  these  first
preliminary results, we tested another experimental variation
focused on concentration range, testing 0.5; 1.0 and 2.0 µg/
mL.  Now,  the  result  was  satisfactory  because  allowed
adequate separation and reproducible measure of inhibition
halos,  as  illustrated  (Figure  2).  So,  one  additional
experiment  was  performed  with  the  defined  analytical
conditions to  test  the reproducibility,  showing satisfactory
results. 
Figure  2.  Illustrative  image  of  a  plate  with  concentration
inoculum  2%,  containing  three  concentrations of imipenem
standard (P) and commercial sample (powder for injection) (A):
A1 and P1 for 0.5 µg/mL; A2 and P2 for 1.0 µg/mL; A3 and P3
for 2.0 µg/mL. Growth on antibiotic media number 11.
Method validation
The validation parameters studied were linearity, precision
(repeatability and intermediate precision) and accuracy. All
analytical procedures followed the official guidelines: ICH
(24) and the Brazilian Health Regulatory Agency (25). 
For  linearity,  it  was  constructed  standard  curves  that
correlates  inhibition halo sizes  with drug concentration  in
logarithmic  values.  For  it,  it  was  obtained  nine  standard
curves in three days of analysis, being three curves a day at
the same conditions.  The standard curves  considered  each
one 8 plates, totalizing 24 plates at the same day. The range
of drug concentration assayed was 0.5; 1.0 and 2.0 µg/mL.
The means  of  halo diameters  for  each  drug concentration
were 15.20 mm (RSD = 2.87); 19.45 mm (RSD = 1.42) and
23.12  mm  (RSD  =  2.76),  respectively.  In  agreement  to
official guidelines, the r value (correlation coefficient) of the
standard  curves  must  be  close  or  equal  1.0,  in  order  to
demonstrate the best linear relation between the variables. In
this  work,  all  curves  obtained  a  r  value  >  0.99,  being
considered very satisfactory. A standard curve obtained in
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Figure 3.  Standard curve correlating diameter of inhibition zone
(mm) versus logarithmic of drug concentration (µg/mL), obtained
from microbiological assay developed to quantitation of imipenem
in powder for injection.
The  linear  regression  analysis  performed  by  ANOVA
(analysis  of  variance)  was  used  to  prove  the  linearity
performance, and not shown deviations from parallelism or
significant differences from the medium values (p-value >
0.05),  as recommended in official  guidelines (17,19).  The
Table 1 illustrates  the ANOVA applied to results of third
day  of  analysis,  considering  results  from  24  plates
(equivalent to three assays with 8 plates).
According to official codes, the evaluation of precision can
be expressed  in  two levels:  repeatability  and  intermediate
precision. As preconized in 3 x 3 design of cylinder plate
assay,  during  precision  both  commercial  sample  and
reference  standard  were  analyzed  in  all  experiments  and
then,  the  imipenem  content  was  calculated.  To  access
repeatability and precision intermediate, results of six assays
with 8 plates were considered in three days of analysis (three
assays with 8 plates  a  day)  and the calculated  RSD were
satisfactory in all the cases (RSD = 0.28-0.64). The mean
drug  content  was  101.05%  (RSD=2.49)  (Table  2).  As
described  in  imipenem  monograph  found  in  US
pharmacopeia, the powder for injection must to contain 90-
115% of imipenem and cilastatin (16).
Microbiological  assay is classified as biological  assay and
generally,  have  a  highly  variation  of  results  (26)  in
comparison with analytical methods like HPLC. Despite of
this, the RSD values obtained in the purposed method were
adequate, being below to 5% for all experiments, showing
that  this  microbiological  assay  is  suitable  to  determine
imipenem in drug formulation despite the inherent variation
of biological assays.
Table 1. Analysis of variance (ANOVA) from quantitative results of linearity (third day) obtained during validation of a microbiological assay
for imipenem in powder for injection.
Variation sources Degrees of freedom Sums of Squares Mean Squares F-calculated F-value
Preparation 1 0.005 0.005 3.88 4.12
Regression 1 509.60 509.60 395424.10 4.12
Desviation from 
paralelism 1 0.000 0.000 0.010 4.12
Quadratic 1 0.003 0.003 2.53 4.12
Quadratic difference 1 0.000 0.000 0.013 4.12
Difference between 
doses 5 509.61 101.92 79086.11 2.48
Difference between 
plates 7 0.009 0.001 0.951 2.29
Table 2. Results obtained from intermediate precision (inter-day)
and  repeatability  (intra-day),  worked  during  validation  of  a
microbiological  assay  for  quantitation  of  imipenem  in  drug
formulation. Data expressed as potency (%) and RSD.
Repeatability
















Intermediate precision 101.05 2.49
a Each result is a mean from three assays of eight plates.
For accuracy, recovery testing was performed according to
described  for  other  microbiological  methods  applied  to
carbapenems  (13,19).  Here,  the  recovery  percentage  was
between 101.70 – 105.20% (mean recovery = 104.86%) with
RSD= 2.95 (Table 3), each result considering three assays
with  six  plates  each  one.  So,  the  recovery  percentage
obtained  was  considered  satisfactory  and  the  method
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Table  3. Mean  values  (%)  of  recovery  test  obtained  from












0.5 0.05 0.051 101.70
1.0 0.10 0.107 107.90
2.0 0.20 0.210 105.20
RSD (%) 2.95
a Each result is a mean from three assays of six plates.
Conclusions
The commercial  samples  of  imipenem were  quantified by
the purposed  microbiological  assay,  whose  validation was
considered  satisfactory.  Linearity,  precision  and  accuracy
were the parameters studied and the results were satisfactory
in  terms  of  official  limits.  So,  the  cylinder-plate  assay
method  can  be  an  analytical  option  for  imipenem
quantitation, in special when the biological potency is useful
for a better comprehension about drug quality. This bioassay
can  be  also  performed  in  a  complementary  view  about
physicochemical  methods  like  UV  spectrophotometry  or
HPLC. 
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